

LincRNAs involved in DCS-induced fear extinction: Shedding light on the transcriptomic dark matter

Stefanie Malan-Müller^{1*}Ψ, Vladimir Barbosa C. de Souza^{2*}, Willie MU Daniels³, Soraya Seedat¹, Mark D. Robinson², Sîan M.J Hemmings¹,

¹ Department of Psychiatry, Stellenbosch University, Cape Town, South Africa

² Institute of Molecular Life Sciences and SIB Swiss Institute of Bioinformatics, University of Zurich, Zurich, Switzerland

³ School of Physiology, University of the Witwatersrand, Johannesburg, South Africa

* Authors contributed equally to the manuscript

Ψ Corresponding author: smalanmul@gmail.com

Authors' ORCID:

Stefanie Malan-Müller: 0000-0003-0639-0129

Vladimir Barbosa C. de Souza:

Willie MU Daniels: 0000-0002-5881-4926

Soraya Seedat: 0000-0002-5118-786X

Mark D. Robinson: 0000-0002-3048-5518

Sîan M.J Hemmings: 0000-0001-8461-1017

There is a growing appreciation of the role of non-coding RNAs in the regulation of gene and protein expression. Long non-coding RNAs can modulate splicing by hybridizing with precursor messenger RNAs (pre-mRNAs) and influence RNA editing, mRNA stability, translation activation and microRNA-mRNA interactions by binding to mature mRNAs. LncRNAs are highly abundant in the brain and have been implicated in neurodevelopmental disorders. Long intergenic non-coding RNAs are the largest subclass of lncRNAs and play a crucial role in gene regulation. We used RNA sequencing and bioinformatic analyses to identify lincRNAs and their predicted mRNA targets associated with fear extinction that was induced by intra-hippocampally administered D-cycloserine in an animal model investigating the core phenotypes of PTSD. We identified 43 differentially expressed fear extinction related lincRNAs and 190 differentially expressed fear extinction related mRNAs. Eight of these lincRNAs were predicted to interact with and regulate 108 of these mRNAs and seven lincRNAs were predicted to interact with 22 of their pre-mRNA transcripts. On the basis of the functions of their target RNAs, we inferred that these lincRNAs bind to nucleotides,

ribonucleotides and proteins and subsequently influence nervous system development, and morphology, immune system functioning, and are associated with nervous system and mental health disorders. Quantitative trait loci that overlapped with fear extinction related lincRNAs, included serum corticosterone level, neuroinflammation, anxiety, stress and despair related responses. This is the first study to identify lincRNAs and their RNA targets with a putative role in transcriptional regulation during fear extinction.

Introduction

Posttraumatic stress disorder (PTSD) is a severe and debilitating disorder that is highly prevalent in individuals who experience one or more traumatic events (1). Dysfunctional fear extinction plays an integral role in the development of the disorder (2)(3). The development of PTSD involves a fear conditioning process, during which fear and anxiety responses are exaggerated and/or are resistant to extinction (4)(5)(6). During classical fear conditioning, a neutral (conditioned) stimulus (CS) is paired with an aversive (unconditioned) stimulus (US). Following adequate pairing of the CS and the US, the CS will eventually result in the same response as the US, and which is referred to as the conditioned response (CR). The CS subsequently has the ability to elicit a conditioned fear response, which can be triggered upon encountering a harmless stimulus associated with the trauma (7). In PTSD, the trauma is considered to be the US, and the conditioned fear response experienced by PTSD patients, even in the presence of seemingly harmless stimuli, is the CR (8)(9).

To relieve the anxiety and fear associated with the CS, deconditioning/desensitization to the learned fears, thus fear extinction, have to occur (10). Systematic desensitization to the CS relies on extinction and counterconditioning, two processes that involve learning. Exposure therapy is dependent on extinction learning to reduce the CR to stimuli that provoke anxiety and panic (11)(12). Recent research has indicated that fear extinction involves the formation of a new competing memory that inhibits the fear response, rather than deleting the original (traumatic) memory (13)(14). Treatment options for PTSD include exposure-based cognitive behavioural therapies (CBT) and pharmacological treatments, such as the selective serotonin reuptake inhibitors (SSRIs) (15) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (16). Despite the relative efficacy of these treatments, a large number of PTSD patients do not respond optimally and/or relapse over time (17)(18)(19).

D-cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist at the glycine site on the NMDAR1 receptor subunit is effective in facilitating extinction learning in rats when administered before or immediately after extinction training (20)(21)(22). The co-administration of DCS and exposure-based CBT has also been proven to be effective in extinguishing fear in human trials of anxiety disorders (23)(24) and PTSD (25)(26). DCS administration facilitates generalized extinction of fear (21) and reduces the rate of relapse following successful exposure-based CBT (27). Studies have investigated the mechanisms of DCS facilitated fear extinction, with the majority focusing on either intra-amygdalar (28) or systemic administration (29)(30) and subsequent investigation of altered gene or protein expression (29). Memory consolidation, and by extension, fear extinction, requires dynamic gene and protein expression regulation; however, few studies have investigated transcriptional and post-transcriptional regulation during fear conditioning and fear extinction.

Only one-fifth of the human transcriptome is associated with protein-coding genes; non-coding RNAs (ncRNAs) are highly prevalent and outnumber coding genes (31). These ncRNAs therefore contribute significantly to the diversification of eukaryotic transcriptomes and proteomes. Currently, 172, 126 human lncRNA transcripts and 24, 879 rat lncRNA transcripts have been identified, encoded for by 96, 000 human and 22, 127 rat lncRNA genes (32). The majority of lncRNA genes are expressed in a cell-type-specific and developmental stage-specific manner (33). LncRNAs are categorized based on their proximity to protein-coding genes. The five categories are sense, antisense, bidirectional, intronic, and intergenic lncRNAs (34)(35). LncRNAs are involved in numerous sub-cellular processes, including cellular organelle formation and functions. Furthermore, lncRNAs are highly abundant in the central nervous system (CNS), and a vast number of neuronal lncRNAs are located adjacent to genes that encode transcriptional regulators and key drivers of neural development, including those involved in the regulation of neuronal differentiation (36), stem cell pluripotency (33), and synaptogenesis (37), implicating these lncRNAs in the regulation of these genes.

Involvement of lncRNAs in such a broad range of functions and processes is likely attributed to their ability to regulate transcription. LncRNAs can regulate the expression of neighbouring genes, both *in-cis* (38)(39) and *-trans* (40)(41) in several ways. One mechanism is promoter modifications, via histone modifications, nucleosome repositioning and DNA

methylation, to either result in chromatin conformations accessible to transcription factors or by inhibiting the nuclear localisation of transcription factors (42), subsequently resulting in activation or repression of gene expression. lncRNAs also participate in RNA processing by hybridizing to mate RNA molecules, thereby influencing mRNA stability, RNA editing, pre-mRNA splicing, translation activation, or abolition of miRNA-induced repression (43). Furthermore, lncRNAs can interact at a protein level through physical interactions with alternative splicing regulators (44), and even act as scaffolds to arrange higher-order complexes, for instance during histone modification (42). Finally, lncRNAs have been implicated as signalling molecules during exosomal RNA transfer between cells, subsequently altering gene expression patterns in the recipient cell (45).

Long intergenic RNAs (lincRNAs) belong to a sub-class of lncRNAs that constitute more than half of lncRNA transcripts in humans (46). RNA sequencing of post-mortem brain samples from schizophrenia and bipolar disorder patients suggests the involvement of lincRNAs in mental disorders (47). A PTSD GWAS study conducted in African American women found a significant association with a novel RNA gene, lincRNA AC068718.1 (48). The authors hypothesised that this lincRNA, with predicted functions for telomere maintenance and immune function, may be a risk factor for PTSD in women. Their results add to emerging evidence that non-coding RNAs play a critical role in gene regulation and might be involved in the aetiology of stress-related disorders (49)(50). However, the modes of action and functions of most lncRNAs in disease remain to be elucidated.

lncRNAs have a rapid turnover rate, thereby providing lncRNAs with the ability to mediate rapid genomic responses to external stimuli, as opposed to the slow-acting response of protein-coding genes (51). lncRNAs of the CNS could, therefore, be involved in rapid cellular and molecular responses, such as those required for memory consolidation or extinction, making them attractive regulators to investigate in pathologies where memory processes are affected. The aim of this project was first, to identify lincRNAs associated with fear extinction as facilitated by the co-administration of behavioural fear extinction and intra-hippocampal DCS administration, in an animal model that simulated the core PTSD phenotypes, and second, to determine the role of these lincRNAs in regulating the transcriptome during fear extinction.

Methods

Animal model

All applicable international, national, and institutional guidelines for the care and use of animals were followed. All animal-related procedures were conducted in accordance with the ethical standards of Stellenbosch University's Research Ethics Committee: Animal Care and Use (REC:ACU) (Ref: ACU/2010/006(A1)).

An adapted version of the PTSD animal model described by Siegmund and Wotjak (2007) was utilised (52). Briefly, 120 adult, male Sprague-Dawley rats were grouped into four experimental groups (30 rats per group) based on an associated fear conditioning paradigm using electric foot shocks. The groups received intrahippocampal administration of either DCS or saline: (1) fear-conditioned + intrahippocampal saline administration (FS), (2) fear-conditioned + intrahippocampal DCS administration (FD), (3) control + intrahippocampal saline administration (CS) and (4) control + intrahippocampal DCS administration (CD). Typical phenotypes associated with PTSD were assessed in this model (53), such as anxious/fearful behaviour (using the light/dark [L/D] avoidance test (54) and open field test (55)) and anhedonia (using the forced swim test (56)). The L/D avoidance test was found in our initial experiments to be the most sensitive behavioural test of anxiety and was subsequently used to differentiate maladapted (animals that displayed anxiety-like behaviour) from well-adapted (animals that did not display anxiety-like behaviour) sub-groups (refer to (57) for more methodological detail).

The following sub-groups are of interest to the current study: (i) control animals that received intra-hippocampal saline (CS, modelling a human control group); (ii) fear-conditioned animals that received intra-hippocampal saline (FS) and were maladapted (FSM, thus modelling a PTSD-like group), fear-conditioned animals that received intra-hippocampal DCS (FD) and were well-adapted (FDW, modelling a patient group exhibiting effective fear extinction due to treatment). We focussed on two sets of sub-group comparisons, namely the FSM vs. CS (modelling the fear conditioning process by comparing a PTSD-like group to controls) and FDW vs. FSM (modelling the fear extinction process by comparing a group that exhibit effective treatment-induced fear extinction to a PTSD-like group), and honed in on differentially expressed transcripts that were regulated in opposite directions in the two

comparison groups. We, therefore, aimed to identify lincRNA and mRNA transcripts that were upregulated in response to fear conditioning in the FSM vs. CS group but downregulated during fear extinction in the FDW vs. FSM group, and *vice versa*, in order to identify lincRNAs and mRNAs specifically associated with the process of fear extinction induced by the co-administration of DCS and behavioural fear extinction (Fig. 1). These sets of opposite, differentially expressed lincRNAs and mRNAs will henceforth be referred to in this manuscript as the fear extinction related lincRNAs and fear extinction related mRNAs.




Figure 1: Diagram to explain animal sub-group comparisons utilised to identify fear extinction related mRNAs and lincRNAs following the co-administration of DCS and behavioural fear extinction

RNA extraction and sequencing

RNA was extracted from the left dorsal hippocampal (LDH) regions of 30 rats (six rats each per FSM, FDW, FSM sub-groups and 12 rats in the CS sub-group) using the RNeasy Plus Mini Kit (Qiagen, Hilden Germany). RNA extraction, quantification and sequencing were performed on the 30 LDH RNA samples as described in (57).

Bioinformatics and statistical analyses

FASTQC was used for quality assessment of RNA sequencing data. To identify differentially expressed transcripts for the sub-group comparisons FSM vs. CS and FDW vs. FSM,

expression was quantified using *Salmon* (version 0.8.2) (58) with the Ensembl release-87 catalogue (coding and non-coding transcripts) (59) and *tximport* (version 1.12.0) (60) was used to import transcript counts into R v3.5.1 (61). We used the *edgeR* package (62) to identify differentially expressed lincRNAs and coding RNAs. The robust generalized linear model approach, as described by Zhou et al., (2014)(63), was used to estimate the dispersion parameter and make inferences for changes in expression.

***In silico* prediction of lincRNA-mediated gene expression regulation during fear extinction**

LincRNAs perform their diverse functions by interacting with a range of molecules, of which RNAs appears to be favoured (64). Therefore, the identification of potential mRNA targets of lincRNAs can help us better understand the functions of lincRNAs and determine how they regulate the transcriptome to facilitate fear extinction. The LncTar tool, developed for large-scale predictions of RNA-RNA interactions (65), was used to identify potential lincRNA–mRNA and lincRNA-pre-mRNA interactions within the sets of fear extinction related lincRNAs and mRNAs. LncTar uses base pairing and determines the minimum free energy joint structure of the two RNA molecules (65). The fasta sequences of fear extinction related lincRNA, mRNA and pre-mRNA transcripts were sourced from ensemble.org and used as the input files. The normalized free energy (ndG) cutoff, which indicates the relative stability of internal base pairs in the paired RNAs (66)(67)(68), was set to the second-highest stringency of - 0.15, to limit the results to interactions with a high probability.

Identifying possible functions of fear extinction related lincRNAs

Although many lincRNAs have been identified, little is known about their functions. The functions of lincRNAs can be deduced from their genomic location or the functions of their targets. To facilitate biological interpretation of large sets of differentially expressed transcripts, gene set enrichment analyses were used to group transcripts together based on their functional similarity (69). To glean information about the functions of the fear extinction related lincRNAs, we investigated the biological processes, molecular functions and pathways (using Comparative Toxicogenomics Database (CTD) (<http://ctdbase.org/tools/analyzer.go>)) (70) and diseases (Rat Genome Database (RGD) (<https://rgd.mcw.edu/rgdweb/enrichment/start.html>)) (71) associated with the predicted

interacting fear extinction related mRNAs. Biological processes and molecular function categories were considered overrepresented if the Bonferroni-corrected p-value was < 0.01 , and for pathways when Bonferroni-corrected p-value was < 0.05 . Only the higher-order parental or ancestral terms for enriched diseases and higher GO levels for biological processes (levels 4 - 6) and molecular functions (levels 3 - 5) will be reported to simplify results and highlight key findings.

LincRNA quantitative trait loci (QTL) overlap

The genomic locations of the fear extinction related lincRNAs were also inspected to determine proximity to QTLs (genes or genomic loci that contribute significantly to the variation in phenotypes/traits (72)), which could suggest putative functions of these lincRNAs (73)(74)(75). RGD (71) was used to identify corresponding RGD names of the fear extinction related lincRNAs and was subsequently used to identify QTLs that overlap with the location of these lincRNAs.

Results

RNA sequencing and differential expression analysis

RNAs with $FDR < 0.05$ and absolute log-fold-change ($\log FC \geq 1$) are illustrated as red points on the minus-add (MA) plot of log-fold-change versus log-counts-per-millions (Fig. 2A). The overlap of detected differentially expressed features were calculated and plotted using the *UpSet* (76) package. An UpSet plot is a visualization approach for the quantitative analysis of sets, their intersections and aggregates of intersections, and serves as an alternative to Venn diagrams (Fig. 2B).




Figure 2: (A) MA (minus-add) plots of log-fold-change (logFC) versus average log-counts-per-millions (logCPM)/ average abundance of lincRNA and mRNA transcripts. The blue dotted lines indicate logFC cut off values of > 1 or < -1. Red points are significantly differentially expressed transcripts (including lincRNAs and mRNAs) at a false discovery rate (FDR) of 5%. **(B)** An UpSet plot illustrating unique and shared differentially expressed lincRNA and mRNA transcripts between the two sub-group comparisons, FSM vs. CS and FDW vs. FSM.

A total of three transcripts were up-regulated in the FSM vs. CS and down-regulated in FDW vs. FSM and a total of 230 transcripts were down-regulated in FSM vs. CS and up-regulated in FDW vs. FSM (Supplementary Tables 1-5). One transcript was down-regulated in both these subgroup comparisons and another transcript was up-regulated in both subgroup comparisons, resulting in a final sum of 235 overlapping transcripts (Fig. 2B) (Supplementary Figures 1-2 show all differentially expressed mRNA and lincRNA transcripts for the two comparison groups). A total of 190 fear extinction related mRNA transcripts were regulated in opposite directions between the two subgroup comparisons of interest ([1] FSM vs. CS and [2] FDW vs. FSM), with three transcripts up-regulated and 187 transcripts down-regulated in the fear conditioning comparison group [1] relative to the fear extinction comparison group [2] (Fig. 3a) (Supplementary Table 6) and 43 lincRNA transcripts were down-regulated in the fear conditioning comparison group [1] relative to the fear extinction comparison group [2] (Fig. 3b) (Supplementary Table 7). A breakdown of the differentially expressed lincRNA and mRNA transcripts is provided in Table 1 (Supplementary Figures 1-2, Supplementary Tables 2-7).



Table 1: Summary of the number of differentially expressed mRNA and lincRNA transcripts for CS vs. FSM and FSM vs. FDW sub-groups

	[1] FSM vs. CS (fear conditioning)	[2] FDW vs. FSM (fear extinction)
Differentially expressed mRNA transcripts (↑/↓)	392 (40/352)	983 (317/666)
Differentially expressed lincRNA transcripts (↑/↓)	55 (2/53)	66 (59/7)
Fear extinction related transcripts		
Opposite mRNA transcripts [1] vs [2] (↑/↓)	190 (3/187)	
Opposite lincRNA transcripts [1] vs [2] (↑/↓)	43 (0/43)	

↑/↓ refers to numbers of upregulated/downregulated transcripts in the first group relative to the comparison group (thus 40 upregulated and 352 downregulated mRNA transcripts in the FSM group relative to the CS group). Opposite transcripts refer to transcripts that were differentially expressed in the fear conditioning [1] FSM vs. CS and fear extinction [2] FDW vs. FSM groups, but in opposite directions (e.g. fear conditioning will result in the downregulation of a particular transcript, and fear extinction will result in the upregulation of that same transcript).

***In silico* prediction of lincRNA-mediated gene expression regulation during fear extinction**

LncTar predicted 119 lincRNA-mRNA interactions (Supplementary Table 8), from the 43 fear extinction related lincRNA transcripts, eight lincRNAs were predicted to interact with 108 fear extinction related mRNAs (Fig. 4). There were nine mRNA transcripts that were targeted by more than one lincRNA and the lincRNA ENSRNOT00000076905 had the highest number of predicted mRNA interactions, yielding 89 in total.




Figure 5: Fear extinction related lincRNA-pre-mRNA transcript interactions. LncTar predicted lincRNA-mRNA transcript interactions; grey circles represent the seven fear extinction related lincRNA transcripts predicted to interact with the 22 fear extinction related pre-mRNA transcripts (red and orange circles). Orange circles represent the nine mRNA transcripts that interacted with more than one lincRNA transcript. Stars indicate the six pre-mRNA transcripts and seven interactions for which there was no corresponding interaction between the lincRNA and its mature mRNA transcript

Table 2: Predicted fear extinction related lincRNAs and pre-mRNAs interactions that may affect splicing

pre-mRNA target	LincRNA	Target region
<i>Glt8d1</i>	ENSRNOT00000076905	intron2
<i>Glt8d1</i>	ENSRNOT00000078727	intron 2, exon3, intron 3
<i>Hp</i>	ENSRNOT00000081808	intron 2, exon 3, intron 3
<i>Nsmf</i>	ENSRNOT00000076905	intron4
<i>LOC499219</i>	ENSRNOT00000076905	intron1
<i>Rtbdn</i>	ENSRNOT00000081808	intron1
<i>Tstd1</i>	ENSRNOT00000076905	intron 3 to exon 4

Glt8d1 - glycosyltransferase 8 domain containing 1 gene, *Hp* – haptoglobin gene, *Nsmf* - NMDA receptor synaptonuclear signaling and neuronal migration factor gene, *LOC499219* – gene transcribing hypothetical protein, *Rtbdn* - retbindin gene, *Tstd1* - thiosulfate sulfurtransferase like domain containing 1 gene, UTR – untranslated region

Gene ontology, disease and pathway enrichment analyses to predict functions of fear extinction related lincRNAs


A total of 81 lincRNA-interacting fear extinction related mRNAs were used in the enrichment analyses, 27 transcripts were clone-based transcripts with unknown functions and were excluded by CTD and RGD databases. Figure 6 shows the most enriched disease (top 25) (Fig. 6a), biological process (Fig. 6b) and molecular function terms (Fig. 6c), based on the Bonferroni corrected p-values and the number of annotated genes for each term (Supplementary Tables 10 – 12 contain exact p-values and all mRNA transcripts associated with each term).

A variety of disease terms were associated with these fear extinction related lincRNAs (Fig. 6a); *Nervous system disease* was the most significant term and several related terms were also enriched for, such as *Brain disease*, *Central nervous system disease* and *Disease of mental health*. A total of 48 mRNA transcripts were associated with these disease terms, of which the lincRNA ENSRNOT00000076905 was predicted to interact with 45 mRNA transcripts. Additional predicted interactions included ENSRNOT00000088470 with *Arhgap26*, ENSRNOT00000080023 with *Rps6kb2* and ENSRNOT00000092675 with *Serpina3n*.


Of the 13 enriched biological process terms, *Neuron projection morphogenesis* and *Nervous system development* were of particular interest (Fig. 6b). A total of 17 mRNA transcripts were associated with these terms, of which the lincRNA ENSRNOT00000076905 interacted with 15 neurogenesis-associated mRNA transcripts (*Add2*, *Baiap2*, *Camk2B*, *Fbxw8*, *Fuz*, *Lamb2*, *Nif3L1*, *Numbl*, *Prdm16*, *Ptpns*, *Rnf157*, *Rock1*, *Syt3*, *Traf3Ip1* and *Trim46*), ENSRNOT00000088470 interacted with *Arhgap26* and ENSRNOT00000076905 interacted with *Baiap2*. Eleven molecular function terms were associated with the lincRNA-interacting mRNA transcripts (Fig. 6c), with the main molecular functions encompassed in the broader terms of nucleotide, ribonucleotide and protein binding. A total of 26 mRNA transcripts were associated with these terms and 24 of these transcripts were predicted to interact with ENSRNOT00000076905. Furthermore, ENSRNOT00000080023 interacted with *Rps6kb2* and ENSRNOT00000088470 interacted with *Arhgap26* (Fig. 5). Two pathways, namely *Immune system* and *Signalling by Rho GTPases*, were associated with 15 of the fear extinction related mRNAs that interacted with the fear extinction related lincRNAs (Supplementary Table 13). Fourteen of these transcripts were predicted to interact with

ENSRNOT00000076905; ENSRNOT00000080023 interacted with *Rps6kb2* and ENSRNOT00000088470 interacted with *Arhgap26* (Fig. 5). The *Oxytocin signalling pathway* was associated with four of the fear extinction related mRNAs, however, the association was not statistically significant (adjusted $p = 0.068$).

a.



b.



C.




Figure 6: (a) Enriched disease terms (top 25), (b) biological processes and (c) molecular functions associated with the 61 fear extinction related mRNAs predicted to interact with fear extinction related lincRNAs. Bars are filled according to the significance level of Bonferroni corrected p-values; significance increases from blue to red.

LincRNA quantitative trait loci (QTL) overlap

To infer possible roles of the fear extinction related lincRNAs that may have regulated the transcription of genes in close proximity; we identified QTLs that overlap with their genomic locations. Four of the 43 fear extinction related lincRNAs had available corresponding RGD names to use in the RGD QTL overlap analysis. Table 3 summarises the most significant ($\text{LOD} \geq 3$, $p\text{-value} < 0.01$) and relevant (in the context of fear extinction) QTLs.

Table 3: LincRNAs that overlap with QTLs of interest

LincRNA	Symbol	QTL Name	LOD	P-Value	Trait	Chr
LOC102549726 ENSRNOT00000081704	Despr15	Despair related QTL 15	NA	0.003	locomotor behaviour trait (VT:0001392)	20
	Scort12	Serum corticosterone level QTL 12	20.46	0.001	blood corticosterone amount (VT:0005345)	
	Scort15	Serum corticosterone level QTL 15	3.48	0.001	blood corticosterone amount (VT:0005345)	
LOC103689920 ENSRNOT00000084136	Anxrr19	Anxiety-related response QTL 19	5.07	NA	body movement coordination trait (VT:0005424)	10
	Neuinf9	Neuroinflammation QTL 9	4.6	NA	nervous system integrity trait (VT:0010566)	
	Scort13	Serum corticosterone level QTL 13	3.26	0.001	blood corticosterone amount (VT:0005345)	
	Scort19	Serum corticosterone level QTL 19	6.3	0.001	blood corticosterone amount (VT:0005345)	

LOC100912578 ENSRNOT00000088478	Stresp21	Stress response QTL 21	3.3	NA	thymus mass (VT:0004954)	3
	Anxrr10	Anxiety-related response QTL 10	3.9	NA	exploratory behaviour trait (VT:0010471)	
	Despr11	Despair related QTL 11		< 0.001	locomotor behaviour trait (VT:0001392)	
	Neuinf11	Neuroinflammation QTL 11	3.9	NA	nervous system integrity trait (VT:0010566)	
	Scort3	Serum corticosterone level QTL 3	23.37	0.001	blood corticosterone amount (VT:0005345)	
LOC102550455 ENSRNOT00000086613	Neuinf7	Neuroinflammation QTL 7	3.4	NA	nervous system integrity trait (VT:0010566)	10

Chr – chromosome, LOD - logarithm of the odds. NA – not available (for certain QTLs either the LOD score or p-value was unavailable on RGD), QTL – quantitative trait loci

Discussion

This study aimed to identify lincRNAs that might be involved in the molecular mechanisms of DCS-facilitated fear extinction. LincRNAs associated with fear conditioning were identified as differentially expressed lincRNAs in FSM vs. CS, and those associated with fear extinction were differentially expressed in FDW vs. FSM, and in the opposite direction as in the FSM vs. CS group, and were referred to as fear extinction related lincRNAs. To determine the functions of these lincRNAs, we identified differentially expressed fear extinction related mRNAs, and used *in silico* prediction software to determine if these lincRNAs may have regulated the expression of these mRNAs or their precursor pre-mRNAs through RNA-RNA hybridisation complexes. Gene ontology enrichment analyses were performed for these targetted mRNAs to identify associated diseases, biological processes, molecular functions and pathways associated with the fear extinction related lincRNAs that targetted these mRNAs. In addition, we identified lincRNAs whose genomic location overlapped with QTLs that could explain why these lincRNAs may be involved in the process of DCS-facilitated fear extinction.

Our prediction analyses indicated that, based on sequence homology, eight lincRNAs could interact with 108 mature mRNA transcripts. These interactions may have influenced RNA editing, mRNA stability, translation activation and miRNA-mRNA interactions of genes that are important for fear extinction (see gene ontology discussion). Seven lincRNAs were predicted to interact with 22 pre-mRNA transcripts. Six of these interactions were not predicted for the corresponding mature mRNA transcripts, where the hybridization occurred in intronic regions or within exon-intron boundaries. We hypothesise that these interactions may influence translation and splicing events in those transcripts. Therefore, the differential

expression of some of the fear extinction related mRNAs could be attributed to alternative splicing of their fear extinction related pre-mRNAs.

Of particular interest was the interaction between ENSRNOT00000076905 and the pre-mRNA of the NMDA receptor synaptonuclear signalling and neuronal migration factor gene (*Nsmf*), since DCS is a partial NMDAR agonist and binding of DCS to NMDARs facilitates extinction learning (20)(21)(22). One study found that an *Nsmf* knockout murine model, deficient for the Jacob protein transcribed by *Nsmf*, exhibited hippocampal dysplasia, impaired BDNF-signaling during dendritogenesis, and phenotypes related to the lack of BDNF-induced nuclear import of Jacob (which is NMDAR-dependent). The authors proposed a role for the Jacob protein in hippocampal dendrite- and synaptogenesis (77). Our data indicated that *Nsmf* was downregulated during fear conditioning (FSM vs. CS), and upregulated during DCS-facilitated fear extinction (FDW vs. FSM), potentially through the activation of NMDARs by DCS, which facilitates nuclear import of the Jacob protein. This could promote dendrite- and synaptogenesis, and possibly facilitate fear extinction. Furthermore, the *Nsmf* gene undergoes extensive splicing, with more than 20 known splice isoforms. The overexpression of one such splice isoform (*Δex9-Jacob*) in primary neurons, resulted in decreased dendritic complexity and number of synapses (78), emphasizing the importance of Jacob splice variants in hippocampal synaptogenesis, a process central to learning and memory (79)(80). Our analysis predicted an interaction between ENSRNOT00000076905 and *Nsmf* pre-mRNA, which may have resulted in alternative splicing, and alternative isoforms of the Jacob protein, with possible implications for hippocampal synaptogenesis and, possibly, fear extinction.

To predict the functions of fear extinction related lincRNAs, we performed gene ontology, and disease and pathway enrichment analyses on the set of predicted fear extinction related mRNA targets (therefore all interactions referred to in the enrichment analyses are fear extinction related transcripts, therefore differentially expressed and in the opposite direction between [1] FSM vs. CS [2] FDW vs. FSM). The most enriched disease term was *Central Nervous system disease*, but other synonymous disease terms were also significant, including *Disease of mental health*. The lincRNA ENSRNOT00000076905 was predicted to interact with the majority of mRNAs enriched in these disease terms (Supplementary Table 10). The likely reason for the vast number of predicted interactions of this lincRNA is its short length (140bp), which increases the likelihood of complementary hybridization to several mRNA transcripts. Additional lincRNAs predicted to interact with mRNAs enriched for central

nervous system disease terms, included ENSRNOT00000088470, ENSRNOT00000080023 and ENSRNOT00000092675. These lincRNAs could, therefore, be involved in diseases that affect the CNS and mental health, by targeting and regulating genes associated with these disease terms.

For biological process enrichment, one lincRNA, ENSRNOT00000076905, was predicted to interact with 15 of the 17 mRNA transcripts involved in nervous system development and neuronal projection (neurogenesis). We hypothesise that this lincRNA is involved in neurogenesis, neuronal projection and extension. The fear extinction protocol consisted of re-exposure to the shock chamber (without shock application), together with intra-hippocampal DCS administration. Our findings, therefore, suggest that DCS facilitated the process of fear extinction by promoting hippocampal neurogenesis. This correlates with earlier findings reporting that hippocampal DCS infusion increased neuronal proliferation and neural plasticity mediated by hippocampal NMDA receptors, which promoted the acquisition and retrieval of extinction memory (81). These results shed further light on the molecular mechanisms behind DCS-facilitated fear extinction, where the lincRNA ENSRNOT00000076905 may interact and regulate the expression of several mRNA transcripts, to ultimately facilitate fear extinction via neurogenesis.

Other predicted lincRNA interactions with mRNAs enriched for the biological process neurogenesis, include that of the brain-specific angiogenesis inhibitor 1-associated protein 2 (*Baiap2*) with ENSRNOT00000076905 and Rho GTPase activating protein 26 (GTPase Regulator) (*Arhgap26*) with ENSRNOT00000088470. The *Baiap2* gene encodes a synaptic protein whose hippocampal expression is required for learning, memory (82) and social competence (83). Furthermore, a SNP in *BALAP2* has been associated with negative modulation of memory strength in humans (84), a process that plays an important role in PTSD (85). A study that investigated early-life programming and related gene x environment interactions in the context of anxiety and depression, found that *Baiap2* was downregulated following prenatal stress exposure (86). We, therefore, hypothesise that DCS administration reversed the negative effect that fear conditioning had on the expression of *Baiap2*, via a proposed ENSRNOT00000076905-mediated upregulation of *Baiap2*, thereby promoting fear extinction learning (87).

The *Arhgap26* gene transcribes a protein that is part of the Rho family of GTPases and interestingly, *Signalling by Rho GTPases* was one of the enriched pathways associated with fear extinction related lincRNAs. This pathway has been implicated in the regulation of learning and memory (88). A proposed mechanism underlying memory formation is the rearrangement of synaptic connections in neural networks. Dendritic spines receive the majority of excitatory synapses (89)(90) and undergo dynamic, experience-dependent changes (91). Furthermore, changes in dendritic spine morphology have been observed during long-term potentiation (LTP), a process that models the activity-dependent changes of synaptic efficacy and the cellular basis of learning (92)(93). Dendritic spine morphology and rearrangement are controlled by the neuronal actin cytoskeleton (94)(95), of which actin assembly, polymerization and actomyosin contraction are mainly regulated by small GTPases of the Rho family (96)(97)(98). LTP induction is associated with actin cytoskeletal reorganization, which is characterized by a sustained increase in F-actin content within dendritic spines. This increased F-actin content is dependent on NMDA receptor activation and involves the inactivation of actin-depolymerizing factor (cofilin) (94). It is thus possible that DCS activated the NMDA receptor, resulting in increased F-actin content and subsequent alterations of neuronal morphology, such as neuronal projection, mediated by Rho GTPases, ultimately facilitating optimal learning and memory (99)(100). We also propose that the lincRNAs ENSRNOT00000076905 and ENSRNOT00000088470 may have been involved in this process by regulating the expression of genes implicated in the Rho GTPase signalling pathway.

Another pathway associated with the fear extinction related lincRNAs was the *immune system*. In recent years, there has been a growing awareness of the importance of the immune system in supporting optimal CNS functioning (101) and the detrimental effects that a dysregulated immune system can evoke on neuronal functioning (102)(103) and mental health (104)(105). Sufficient immune functioning not only supports optimal stress-coping responses, but is also essential for learning and memory (101)(102)(103). In this study, DCS may have facilitated fear extinction by regulating the expression of immune-related genes via lincRNAs such as ENSRNOT00000080023 and ENSRNOT00000076905.

As expected, the main molecular functions associated with fear extinction related lincRNAs were nucleotide, ribonucleotide and cytoskeletal protein binding, since the main features of lincRNAs are the regulation of gene and protein expression through its interactions with

chromatin and RNAs or by recruiting and interacting with transcriptional repressors or enhancers (as reviewed by (106)). LncRNAs can even interact with DNA and one mechanism involved in direct RNA–DNA interactions are triple helices. Double-stranded DNA forms triple-helical structures by incorporating a third single-stranded nucleic acid in its major groove, forming Hoogsteen or reverse Hoogsteen hydrogen bonds with a purine-rich strand of DNA (107). Interestingly, other enriched molecular functions included purine nucleotide-binding and purine ribonucleotide binding. In the nucleus, these triple-helical structures (containing ribosomal DNA [rDNA] and lincRNA) are recognized by DNA methyltransferase DNMT3B, which methylates rDNA promoters and subsequently represses rDNA transcription (108). Moreover, certain lncRNAs directly interact with DNA in a sequence-specific manner and subsequently activates (109)(110) or repress transcription (111)(112) through the recruitment of coactivator or corepressor proteins. Some lncRNAs can also form triple helices in *cis* (auto-binding) (111)(110)(113), therefore enabling regulation of the exact locations they are transcribed from. Our findings therefore not only highlight the main functions of lincRNAs but also point to directions for future research, namely interrogation of lincRNA-DNA interactions and their subsequent effects on transcriptional and translational regulation.

LncRNAs can regulate the expression of neighbouring genes *in-cis* (38)(39). We therefore identified QTLs that overlapped with the genomic regions of four fear extinction related lincRNAs for which there was an RGD ID available (ENSRNOT00000081704, ENSRNOT00000084136, ENSRNOT00000088478 and ENSRNOT00000086613). The selected QTLs of interest were involved in traits such as serum corticosterone level, neuroinflammation as well as anxiety, stress and despair related responses. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis results in an inability to initiate a normal stress response, which is a key feature of PTSD. The HPA axis is regulated by a negative feedback mechanism, where excess cortisol (or corticosterone in rodents) binds to glucocorticoid receptors in the hypothalamus and pituitary and subsequently suppresses the release of corticotropin-releasing hormone and adrenocorticotropin hormone. The HPA-axis also interacts with the immune system to maintain homeostasis (Wong et al., 2002) and there is an intricate relationship between the immune system, brain and behaviour, as discussed earlier. Research has also shown that immune functioning is affected in PTSD patients (114)(115)(116). We, therefore, hypothesise that the upregulation of these lincRNAs, following DCS administration, may result in the *cis*-regulation of genes that control cortisone

levels and neuroinflammation, which elicited downstream effects on learning and memory to ultimately alleviate anxiety and stress-related responses and promote successful fear extinction.

Conclusion

This study employed bioinformatics, *in silico* interaction prediction and gene set enrichment analyses to identify differentially expressed lincRNAs that may have targeted and regulated the expression of mRNAs that are enriched in biological processes, molecular functions and pathways that mediate fear extinction. Future studies could build on the *in silico* results by using cell-culture based assays to functionally verify predicted lincRNA-mRNA interactions. Protein quantification of predicted mRNA targets should also be performed; unfortunately, due to the limited quantity of hippocampal tissue, we could not determine whether changes in gene expression translated to altered protein expression in this model.

This is the first study to identify lincRNAs and their RNA targets that play a role in transcriptional regulation during fear extinction. Our research identified differentially expressed lincRNAs and their predicted mRNA and pre-mRNA targets that could help us decipher the molecular basis of DCS-induced fear extinction. Four hippocampal lincRNAs, ENSRNOT00000076905, ENSRNOT00000088470, ENSRNOT00000080023 and ENSRNOT00000092675, interacted with nucleotides, ribonucleotides and proteins, thereby regulating the expression of genes involved in neuronal projection and neurogenesis, a dynamic process required during learning and memory, which was possibly mediated by the Rho GTPase pathway. Through the regulation of serum corticosterone levels, and subsequently, the HPA-axis, lincRNAs ENSRNOT00000081704, ENSRNOT00000084136, ENSRNOT00000088478 and ENSRNOT00000086613 may also have attenuated anxiety, stress and despair related responses through improved neuro-immune functioning. These eight lincRNAs were important role players in a well orchestrated sequence of events that resulted in effective fear extinction in this model investigating the core phenotypes of PTSD.

Acknowledgements

This work is based on research supported by the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South

Africa, as well as the South African Medical Research Council (SAMRC) under a Self-Initiated Research Grant. Thank you to Dr Fairbairn-Adonis for performing the animal work. A special thanks to Dr Oakeley and Novartis Pharma (Basel) for performing the RNA sequencing. MDR acknowledges support from the University Research Priority Program Evolution in Action at the University of Zurich. VBCS acknowledges support from the Brazilian institution *Conselho Nacional de Desenvolvimento Científico e Tecnológico* (CNPq).

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [Internet]. Fifth Edition. American Psychiatric Association; 2013 [cited 2019 Sep 5]. Available from: <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596>
2. Milad MR, Pitman RK, Ellis CB, Gold AL, Rauch SL. Neurobiological Basis of Failure to Recall Extinction Memory in Posttraumatic Stress Disorder. *Biol Psychiatry*. 2009;66:1075–82.
3. Garfinkel SN, Abelson JL, King AP, Sripada RK, Wang XX, Gaines LM, et al. Impaired contextual modulation of memories in PTSD: an fMRI and psychophysiological study of extinction retention and fear renewal. *J Neurosci Off J Soc Neurosci*. 2014;34(40):13435–43.
4. Caddell TKZ. A behavioral formulation of Post-traumatic Stress Disorder in Vietnam veterans. 1984 Dec 31 [cited 2019 Oct 30]; Available from: <https://www.rti.org/publication/behavioral-formulation-post-traumatic-stress-disorder-vietnam-veterans>
5. Cohen H, Zohar J, Gidron Y, Matar MA, Belkind D, Loewenthal U, et al. Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. *Biol Psychiatry*. 2006 Jun 15;59(12):1208–18.
6. Amstadter AB, Nugent NR, Koenen KC. Genetics of PTSD: Fear Conditioning as a Model for Future Research. *Psychiatr Ann*. 2009 Jun 1;39(6):358–67.
7. Estes WK, Skinner BF. Some Quantitative Properties of Anxiety. *J Exp Psychol*. 1941;29(5):390.
8. Foa EB, Steketee G, Rothbaum BO. Behavioral/cognitive conceptualizations of post-traumatic stress disorder. *Behav Ther*. 1989 Mar 1;20(2):155–76.
9. Grillon C, Morgan CA, Davis M, Southwick SM. Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. *Biol Psychiatry*. 1998 Nov 15;44(10):1027–36.
10. Wolpe J. Psychotherapy by reciprocal inhibition. *Cond Reflex*. 1968 Dec;3(4):234–40.
11. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. *Psychol Rev*. 2001 Jan;108(1):4–32.
12. Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. *Ann N Y Acad Sci*. 2003 Dec;1008:112–21.
13. pubmeddev, GJ MM and Q. Fear extinction as a model for translational neuroscience: ten years of progress. - PubMed - NCBI [Internet]. [cited 2019 Sep 5]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/22129456/>
14. Rescorla RA, Heth CD. Reinstatement of fear to an extinguished conditioned stimulus. *J Exp Psychol Anim Behav Process*. 1975;1(1):88–96.
15. Stein DJ, Ipser JC, Seedat S, Sager C, Amos T. Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev* [Internet]. 2006 [cited 2019 Sep 5];(1). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002795.pub2/full?cookiesEnabled>

16. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, et al. Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release: A 6-Month Randomized Controlled Trial. *Arch Gen Psychiatry*. 2006 Oct 1;63(10):1158–65.
17. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic Stress Disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1995 Dec 1;52(12):1048–60.
18. Marit Sijbrandij MA, Miranda Olff PD, Johannes B. Reitsma MD, Ingrid V. E. Carlier PD, Mirjam H. de Vries MA, Berthold P. R. Gersons MD. Treatment of Acute Posttraumatic Stress Disorder With Brief Cognitive Behavioral Therapy: A Randomized Controlled Trial. *Am J Psychiatry* [Internet]. 2007 Jan 1 [cited 2019 Sep 5]; Available from: <https://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.2007.164.1.82>
19. Foa E, A Zoellner L, Feeny N. An evaluation of three brief programs for facilitating recovery after assault. *J Trauma Stress*. 2006 Feb 1;19:29–43.
20. Ledgerwood L, Richardson R, Cranney J. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. *Behav Neurosci* 117: 341-349. *Behav Neurosci*. 2003 May 1;117:341–9.
21. Ledgerwood L, Richardson R, Cranney JS. d-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. *Biol Psychiatry*. 2005;57:841–7.
22. Yang YL, Lu KT. Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. *Neuroscience*. 2005 Jan 1;134(1):247–60.
23. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder. *Arch Gen Psychiatry*. 2006 Mar 1;63(3):298–304.
24. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder. *Biol Psychiatry*. 2010 Feb 15;67(4):365–70.
25. de Kleine RA, Hendriks G-J, Kusters WJC, Broekman TG, van Minnen A. A Randomized Placebo-Controlled Trial of d-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder. *Biol Psychiatry*. 2012 Jun 1;71(11):962–8.
26. Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS, et al. D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial. *Neuropsychopharmacology*. 2014 Apr;39(5):1052–8.
27. Ledgerwood L, Richardson R, Cranney J. D-Cycloserine and the Facilitation of Extinction of Conditioned Fear: Consequences for Reinstatement. *Behav Neurosci*. 2004;118(3):505–13.
28. Mao S-C, Hsiao Y-H, Gean P-W. Extinction training in conjunction with a partial agonist of the glycine site on the NMDA receptor erases memory trace. *J Neurosci Off J Soc Neurosci*. 2006 Aug 30;26(35):8892–9.
29. Yamamoto S, Morinobu S, Fuchikami M, Kurata A, Kozuru T, Yamawaki S. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2008 Aug;33(9):2108–16.
30. Gabriele A, Packard MG. D-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinction. *Learn Mem Cold Spring Harb N*. 2007 Jul;14(7):468–71.
31. Kapranov P, St Laurent G, Raz T, Oszlak F, Reynolds CP, Sorensen PH, et al. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is “dark matter” un-annotated RNA. *BMC Biol*. 2010 Dec 21;8(1):149.
32. Fang S, Zhang L, Guo J, Niu Y, Wu Y, Li H, et al. NONCODEV5: a comprehensive annotation database for long non-coding RNAs. *Nucleic Acids Res*. 2018 04;46(D1):D308–14.
33. Ramos AD, Diaz A, Nellore A, Delgado RN, Park K-Y, Gonzales-Roybal G, et al. Integration of genome-wide approaches identifies lncRNAs of adult neural stem cells and their progeny in vivo. *Cell Stem Cell*. 2013 May 2;12(5):616–28.
34. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet*. 2009 Mar;10(3):155–9.

35. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. *Cell*. 2009 Feb 20;136(4):629–41.
36. Onoguchi M, Hirabayashi Y, Koseki H, Gotoh Y. A noncoding RNA regulates the neurogenin1 gene locus during mouse neocortical development. *Proc Natl Acad Sci U S A*. 2012 Oct 16;109(42):16939–44.
37. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z, et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. *EMBO J*. 2010 Sep 15;29(18):3082–93.
38. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. *RNA Biol*. 2013 Jun;10(6):925–33.
39. Maenner S, Blaud M, Fouillen L, Savoye A, Marchand V, Dubois A, et al. 2-D Structure of the A Region of Xist RNA and Its Implication for PRC2 Association. *PLOS Biol*. 2010 Jan 5;8(1):e1000276.
40. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell*. 2011 Sep 16;43(6):904–14.
41. Elling R, Robinson EK, Shapleigh B, Liapis SC, Covarrubias S, Katzman S, et al. Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2. *Cell Rep*. 2018 Nov 6;25(6):1511–1524.e6.
42. Kugel JF, Goodrich JA. Non-coding RNAs: key regulators of mammalian transcription. *Trends Biochem Sci*. 2012 Apr;37(4):144–51.
43. Geisler S, Collier J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nat Rev Mol Cell Biol*. 2013 Nov;14(11):699–712.
44. Yin Q-F, Yang L, Zhang Y, Xiang J-F, Wu Y-W, Carmichael GG, et al. Long noncoding RNAs with snoRNA ends. *Mol Cell*. 2012 Oct 26;48(2):219–30.
45. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. *BMC Genomics*. 2013 May 10;14:319.
46. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. *Nat Rev Mol Cell Biol*. 2018;19(3):143–57.
47. Hu J, Xu J, Pang L, Zhao H, Li F, Deng Y, et al. Systematically characterizing dysfunctional long intergenic non-coding RNAs in multiple brain regions of major psychosis. *Oncotarget*. 2016 Sep 19;7(44):71087–98.
48. Guffanti G, Galea S, Yan L, Roberts AL, Solovieff N, Aiello AE, et al. Genome-wide association study implicates a novel RNA gene, the lincRNA AC068718.1, as a risk factor for post-traumatic stress disorder in women. *Psychoneuroendocrinology*. 2013 Dec;38(12):3029–38.
49. Cui X, Niu W, Kong L, He M, Jiang K, Chen S, et al. Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder. *Indian J Psychiatry*. 2017;59(1):83–7.
50. Ren Y, Cui Y, Li X, Wang B, Na L, Shi J, et al. A co-expression network analysis reveals lncRNA abnormalities in peripheral blood in early-onset schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015 Dec 3;63:1–5.
51. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P, et al. Genome-wide analysis of long noncoding RNA stability. *Genome Res*. 2012 May;22(5):885–98.
52. Siegmund A, Wotjak CT. A mouse model of posttraumatic stress disorder that distinguishes between conditioned and sensitised fear. *J Psychiatr Res*. 2007 Nov 1;41(10):848–60.
53. Ritov G, Boltyansky B, Richter-Levin G. A novel approach to PTSD modeling in rats reveals alternating patterns of limbic activity in different types of stress reaction. *Mol Psychiatry*. 2016 May;21(5):630–41.
54. Serchov T, van Calker D, Biber K. Light/Dark Transition Test to Assess Anxiety-like Behavior in Mice. *BIO-Protoc [Internet]*. 2016 [cited 2019 Oct 30];6(19). Available from: <https://bio-protocol.org/e1957>
55. Cryan JF, Sweeney FF. The age of anxiety: role of animal models of anxiolytic action in drug discovery. *Br J Pharmacol*. 2011 Oct;164(4):1129–61.
56. Strekalova T, Spanagel R, Bartsch D, Henn FA, Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2004 Nov;29(11):2007–17.

57. Malan-Müller S, Fairbairn L, Daniels WMU, Dashti MJS, Oakeley EJ, Altorfer M, et al. Molecular mechanisms of D-cycloserine in facilitating fear extinction: insights from RNAseq. *Metab Brain Dis.* 2016 Feb;31(1):135–56.
58. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. *Nat Methods.* 2017 Apr;14(4):417–9.
59. Kersey PJ, Allen JE, Allot A, Barba M, Boddu S, Bolt BJ, et al. Ensembl Genomes 2018: an integrated omics infrastructure for non-vertebrate species. *Nucleic Acids Res.* 2018 04;46(D1):D802–8.
60. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Research.* 2015;4:1521.
61. R: The R Project for Statistical Computing [Internet]. [cited 2019 Sep 6]. Available from: <https://www.r-project.org/>
62. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinforma Oxf Engl.* 2010 Jan 1;26(1):139–40.
63. Zhou X, Lindsay H, Robinson MD. Robustly detecting differential expression in RNA sequencing data using observation weights. *Nucleic Acids Res.* 2014 Jun;42(11):e91.
64. Yamamura S, Imai-Sumida M, Tanaka Y, Dahiya R. Interaction and cross-talk between non-coding RNAs. *Cell Mol Life Sci CMLS.* 2018 Feb;75(3):467–84.
65. Li J, Ma W, Zeng P, Wang J, Geng B, Yang J, et al. LncTar: a tool for predicting the RNA targets of long noncoding RNAs. *Brief Bioinform.* 2015 Sep;16(5):806–12.
66. Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. *RNA.* 2004 Oct;10(10):1507.
67. Dimitrov R, Zuker M. Prediction of Hybridization and Melting for Double-Stranded Nucleic Acids. *Biophys J.* 2004 Aug 1;87:215–26.
68. Markham NR, Zuker M. UNAFold: software for nucleic acid folding and hybridization. *Methods Mol Biol.* 2008;453:3–31.
69. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. *Nat Protoc.* 2007 Oct;2(10):2366–82.
70. Davis AP, Grondin C, J Johnson R, Sciaky D, McMorran R, Wieggers J, et al. The Comparative Toxicogenomics Database: update 2019. *Nucleic Acids Res.* 2018 Sep 24;47.
71. Twigger S, Lu J, Shimoyama M, Chen D, Pasko D, Long H, et al. Rat Genome Database (RGD): mapping disease onto the genome. *Nucleic Acids Res.* 2002 Jan 1;30(1):125.
72. Zeng ZB. Precision mapping of quantitative trait loci. *Genetics.* 1994 Apr 1;136(4):1457–68.
73. Li A, Zhang J, Zhou Z, Wang L, Liu Y, Liu Y. ALDB: A Domestic-Animal Long Noncoding RNA Database. *PLOS ONE.* 2015 Apr 8;10(4):e0124003.
74. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev.* 2011 Sep 15;25(18):1915–27.
75. Kutter C, Watt S, Stefflova K, Wilson MD, Goncalves A, Ponting CP, et al. Rapid Turnover of Long Noncoding RNAs and the Evolution of Gene Expression. *PLOS Genet.* 2012 Jul 26;8(7):e1002841.
76. Lex A, Gehlenborg N, Strobel H, Vuilleumot R, Pfister H. UpSet: Visualization of Intersecting Sets. *IEEE Trans Vis Comput Graph.* 2014 Dec;20(12):1983–92.
77. Spilker C, Grochowska KM, Kreutz MR. What do we learn from the murine Jacob/Nsmf gene knockout for human disease? *Rare Dis Austin Tex.* 2016;4(1):e1241361.
78. Dieterich DC, Karpova A, Mikhaylova M, Zdobnova I, König I, Landwehr M, et al. Caldendrin–Jacob: A Protein Liaison That Couples NMDA Receptor Signalling to the Nucleus. *PLOS Biol.* 2008 Feb 26;6(2):e34.
79. Klintsova AY, Greenough WT. Synaptic plasticity in cortical systems. *Curr Opin Neurobiol.* 1999 Apr;9(2):203–8.
80. Geinisman Y, Berry RW, Disterhoft JF, Power JM, Zee EAV der. Associative Learning Elicits the Formation of Multiple-Synapse Boutons. *J Neurosci.* 2001 Aug 1;21(15):5568–73.

81. Ren J, Li X, Zhang X, Li M, Wang Y, Ma Y. The effects of intra-hippocampal microinfusion of D-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013 Jul 1;44:257–64.
82. Kim M-H, Choi J, Yang J, Chung W, Kim J-H, Paik SK, et al. Enhanced NMDA receptor-mediated synaptic transmission, enhanced long-term potentiation, and impaired learning and memory in mice lacking IRSp53. *J Neurosci Off J Soc Neurosci*. 2009 Feb 4;29(5):1586–95.
83. Chung W, Choi SY, Lee E, Park H, Kang J, Park H, et al. Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. *Nat Neurosci*. 2015 Mar;18(3):435–43.
84. Luksys G, Ackermann S, Coynel D, Fastenrath M, Gschwind L, Heck A, et al. BAIAP2 is related to emotional modulation of human memory strength. *PloS One*. 2014;9(1):e83707.
85. Parsons RG, Ressler KJ. Implications of memory modulation for post-traumatic stress and fear disorders. *Nat Neurosci*. 2013 Feb;16(2):146–53.
86. Jakob S. Molecular mechanisms of early-life stress in 5-Htt deficient mice: Gene x environment interactions and epigenetic programming. [cited 2019 Oct 24]; Available from: <https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/6310>
87. Fischer DU, Dandekar DT, Gross DC. Members of the Promotionskomitee: :126.
88. Diana G, Valentini G, Travaglione S, Falzano L, Pieri M, Zona C, et al. Enhancement of learning and memory after activation of cerebral Rho GTPases. *Proc Natl Acad Sci U S A*. 2007 Jan 9;104(2):636–41.
89. Harris KM. Structure, development, and plasticity of dendritic spines. *Curr Opin Neurobiol*. 1999 Jun;9(3):343–8.
90. Nimchinsky EA, Sabatini BL, Svoboda K. Structure and function of dendritic spines. *Annu Rev Physiol*. 2002;64:313–53.
91. Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, et al. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. *Nature*. 2002 Dec 19;420(6917):788–94.
92. Lang C, Barco A, Zablow L, Kandel ER, Siegelbaum SA, Zakharenko SS. Transient expansion of synaptically connected dendritic spines upon induction of hippocampal long-term potentiation. *Proc Natl Acad Sci U S A*. 2004 Nov 23;101(47):16665–70.
93. Muller D, Toni N, Buchs PA. Spine changes associated with long-term potentiation. *Hippocampus*. 2000;10(5):596–604.
94. Fukazawa Y, Saitoh Y, Ozawa F, Ohta Y, Mizuno K, Inokuchi K. Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. *Neuron*. 2003 May 8;38(3):447–60.
95. Zito K, Knott G, Shepherd GMG, Shenolikar S, Svoboda K. Induction of spine growth and synapse formation by regulation of the spine actin cytoskeleton. *Neuron*. 2004 Oct 14;44(2):321–34.
96. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. *Nat Cell Biol*. 1999 Sep;1(5):253–9.
97. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science*. 1996 Jul 12;273(5272):245–8.
98. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. *Science*. 1999 Aug 6;285(5429):895–8.
99. Luo L, Hensch TK, Ackerman L, Barbel S, Jan LY, Jan YN. Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines. *Nature*. 1996 Feb 29;379(6568):837–40.
100. Tashiro A, Minden A, Yuste R. Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. *Cereb Cortex N Y N 1991*. 2000 Oct;10(10):927–38.
101. Besedovsky HO, del Rey A. Central and Peripheral Cytokines Mediate Immune-Brain Connectivity. *Neurochem Res*. 2011 Jan 1;36(1):1–6.

102. Molina-Holgado E, Molina-Holgado F. Mending the broken brain: neuroimmune interactions in neurogenesis. *J Neurochem*. 2010;114(5):1277–90.
103. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. *Brain Behav Immun*. 2011;25:181–213.
104. Zass LJ, Hart SA, Seedat S, Hemmings SMJ, Malan-Müller S. Neuroinflammatory genes associated with post-traumatic stress disorder: implications for comorbidity. *Psychiatr Genet*. 2017 Feb;27(1):1–16.
105. Pariante CM. Depression during pregnancy: molecular regulations of mothers' and children's behaviour. *Biochem Soc Trans*. 2014 Apr;42(2):582–6.
106. Dykes IM, Emanuelli C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. *Genomics Proteomics Bioinformatics*. 2017;15(3):177–86.
107. Broitman SL, Im DD, Fresco JR. Formation of the triple-stranded polynucleotide helix, poly(A.A.U). *Proc Natl Acad Sci U S A*. 1987 Aug;84(15):5120–4.
108. Schmitz K-M, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. *Genes Dev*. 2010 Oct 15;24(20):2264–9.
109. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, et al. *MEG3* long noncoding RNA regulates the TGF- β pathway genes through formation of RNA–DNA triplex structures. *Nat Commun*. 2015 Jul 24;6:7743.
110. Postepska-Igielska A, Giwojna A, Gasri-Plotnitsky L, Schmitt N, Dold A, Ginsberg D, et al. LncRNA *Khps1* Regulates Expression of the Proto-oncogene *SPHK1* via Triplex-Mediated Changes in Chromatin Structure. *Mol Cell*. 2015 Nov 19;60(4):626–36.
111. Grote P, Wittler L, Hendrix D, Koch F, Währisch S, Beisaw A, et al. The tissue-specific lncRNA *Fendrr* is an essential regulator of heart and body wall development in the mouse. *Dev Cell*. 2013 Jan 28;24(2):206–14.
112. Kalwa M, Hänzelmann S, Otto S, Kuo C-C, Franzen J, Joussen S, et al. The lncRNA *HOTAIR* impacts on mesenchymal stem cells via triple helix formation. *Nucleic Acids Res*. 2016 Dec 15;44(22):10631–43.
113. Zhao Z, Sentürk N, Song C, Grummt I. lncRNA *PAPAS* tethered to the rDNA enhancer recruits hypophosphorylated CHD4/NuRD to repress rRNA synthesis at elevated temperatures. *Genes Dev*. 2018 01;32(11–12):836–48.
114. Morath J, Gola H, Sommershof A, Hamuni G, Kolassa S, Catani C, et al. The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: Evidence from a randomized controlled trial. *J Psychiatr Res*. 2014 Jul;54:1–10.
115. Heath NM, Chesney SA, Gerhart JJ, Goldsmith RE, Luborsky JL, Stevens NR, et al. Interpersonal violence, PTSD, and inflammation: potential psychogenic pathways to higher C-reactive protein levels. *Cytokine*. 2013 Aug;63(2):172–8.
116. Eraly SA, Nievergelt CM, Maihofer AX, Barkauskas DA, Biswas N, Agorastos A, et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. *JAMA Psychiatry*. 2014 Apr;71(4):423–31.